click the link above
Dr. Nallasivam Palanisamy is on a journey of discovery. His destination is finding novel biomarkers to improve the diagnosis and treatment of prostate cancer.
He and his team in the Department of Urology at Henry Ford Health know that identifying molecular markers in solid cancers has eluded conventional cytogenetic and molecular methods for decades.
But Dr. Palanisamy thinks a better approach entails unbiased, comprehensive genomic and transcriptomic characterization via high-throughput, massively parallel sequencing.
